Key facts
- InvenireX’s last known valuation is $4.1M (Aug 2025).
- It has raised $3.9M; the latest was Early Stage VC ($2.7M) in Aug 2025.
- Notable investors include Innovate UK, XTX Ventures, Cambridge Technology Capital Fund, ConceptionX, DSW Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for InvenireX
- ·The full record, as it builds
Funding rounds
No funding rounds for InvenireX are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InvenireX
Developer of a molecular diagnostics platform designed to democratize and accelerate life science research. The company's platform possesses limits of detection, several orders of magnitude lower than current, commonly used diagnostic methods of detection, enabling biotech researchers to live detection of nucleic acids, ribonucleic acid, and proteins through video-feed with single-molecule precision using artificial intelligence.
- Sector
- Healthcare
- HQ
- Newcastle Upon Tyne, United Kingdom
- Founded
- 2021
- Employees
- 10
- Website
- invenirex.co.uk/
- Ownership
- Privately Held (backing)
InvenireX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InvenireX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InvenireX in its N-PORT filings yet. We sweep new filings monthly.